Probiotics ameliorates glycemic control of patients with diabetic nephropathy: A randomized clinical study

• Main Authors: Jiang, H. (Author), Wang, Q. (Author), Xu, D. (Author), Zhang, Y. (Author)
• Format: Article
• Language: English
• Published: John Wiley and Sons Inc 2021
• Subjects: adult; albuminuria; Albuminuria; Article; Bifidobacterium bifidum; blood; Blood Glucose; clinical evaluation; complication; controlled study; creatinine; Creatinine; Diabetic Nephropathies; diabetic nephropathy; diabetic patient; diet restriction; double blind procedure; estimated glomerular filtration rate; Fasting; female; Female; Glomerular Filtration Rate; glomerulus filtration rate; glucose blood level; Glycated Hemoglobin A; glycemic control; Glycemic Control; glycosylated hemoglobin; human; Humans; kidney function; Lactobacillus acidophilus; major clinical study; male; Male; metabolism; microalbuminuria; middle aged; Middle Aged; pathophysiology; placebo; Placebos; Postprandial Period; postprandial state; probiotic agent; probiotics; Probiotics; randomized controlled trial; Streptococcus thermophilus; therapy effect; type 2 diabetes mellitus
• Online Access: View Fulltext in Publisher

 Objective: This research aimed to explore the effects of probiotic administration on glycemic control and renal function in patients with diabetic nephropathy (DN). Methods: The 101 participants were randomly divided into two treatment groups and 76 patients were included in the final analysis. In 76 patients with diabetic nephropathy of type 2 diabetes, a randomized double-blind and placebo-controlled clinical trial was conducted to evaluate the administration of 3.2 × 109 CFU probiotic supplements per day (Bifidobacterium bifidum, 1.2 × 109 CFU, Lactobacillus acidophilus 4.2 × 109 CFU, Streptococcus thermophilus 4.3 × 109 CFU) for 12 weeks on glycemic control of patients, including fasting blood glucose, 2 h postprandial blood glucose, glycosylated hemoglobin (HbA1c), microalbuminuria/creatinine (mAlb/Cr) and estimated glomerular filtration rate (eGFR) levels. The placebo group daily received empty capsules filled with starch. Results: After 12 weeks, the administration of probiotics demonstrated a significant reduction in fasting blood glucose (10.68 ± 3.24 mmol/L before vs. 7.81 ± 2.77 mmol/L after, p < 0.05), HbA1c (8.19 ± 1.60% before vs. 7.32 ± 1.20% after, p < 0.05) and mAlb/Cr (101.60 ± 22.17 mg/g before vs. 67.53 ± 20.11 mg/g after, p < 0.05), while only mAlb/Cr level was significantly lower in the probiotic group than in the placebo group after intervention (67.53 ± 20.11 mg/g vs. 87.71 ± 23.01, p < 0.05). Meanwhile, there was no significant reduction of 2 h postprandial blood glucose level (18.95 ± 5.23 mmol/L vs. 17.35 ± 6.28 mmol/L, p = 0.24) and eGFR (84.34 ± 6.97 ml/min vs. 82.8 ± 8.72 ml/min, p = 0.45) in patients before and after probiotic intake. In addition, the placebo group failed to show any significant change of these parameters. Conclusion: This clinical study revealed probiotic administration could ameliorate glycemic control of patients with diabetic nephropathy, potentiating its therapeutic potential in clinical application. © 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.